Cetraria Islandica Subsp. Islandica

Dosage for Cetraria Islandica Subsp. Islandica is highly individualized, particularly when used for immunotherapy.

• Diagnostic Skin Prick Testing: Typically, one drop of the non-standardized extract (often 1:10 or 1:20 w/v) is applied to the skin, followed by a prick with a sterile lancet. Results are read after 15–20 minutes.
• Subcutaneous Immunotherapy (SIT): Dosing follows a 'build-up' phase and a 'maintenance' phase.
• Build-up Phase: Starting doses may be as low as 0.05 mL of a highly diluted extract (e.g., 1:100,000), increasing weekly or bi-weekly based on patient tolerance until the maintenance dose is reached.
• Maintenance Phase: Usually involves injections of 0.5 mL of the most concentrated tolerated extract (e.g., 1:100 or 1:10) every 4 to 8 weeks.
• Oral Demulcent Use: When used as a throat lozenge, the typical dose is 100–200 mg of extract taken 3–6 times daily as needed for irritation.

Cetraria Islandica Subsp. Islandica extracts should be used with extreme caution in children.

• Diagnostic Testing: Approved for use in children as young as 2 years old under strict medical supervision. The procedure is identical to adult testing, but the number of simultaneous tests may be limited to prevent systemic reactions.
• Immunotherapy: Generally not recommended for children under 5 years of age due to the difficulty of communicating early symptoms of systemic reactions (anaphylaxis).
• Oral Use: Pediatric lozenges may be used in children over 6 years old, typically at half the adult frequency.

Renal Impairment

No specific dosage adjustments are required for diagnostic skin testing in patients with renal impairment. However, for systemic immunotherapy, patients with severe renal disease should be monitored closely for any changes in the clearance of lichen acids, although proteinaceous antigens are largely degraded locally or by proteases.

Hepatic Impairment

Patients with significant hepatic impairment (Child-Pugh Class B or C) may have altered metabolism of the secondary metabolites (lichen acids). While not a contraindication for testing, these patients should be monitored for unusual systemic side effects if large doses are used in immunotherapy.

Elderly Patients

Elderly patients (65+) may have reduced skin reactivity, leading to potential false-negative results in diagnostic testing. Furthermore, the risk of cardiovascular complications from a systemic reaction (anaphylaxis) is higher in this population. Healthcare providers may choose more conservative starting doses for immunotherapy in the elderly.

• For Injections: These must ALWAYS be administered by a healthcare professional in a facility equipped with emergency resuscitation equipment (epinephrine, oxygen, etc.). Patients must remain in the clinic for at least 30 minutes following the injection.
• For Oral Lozenges: Allow the lozenge to dissolve slowly in the mouth. Do not chew or swallow whole. Avoid eating or drinking for 15 minutes after use to allow the mucilage to coat the throat.
• Storage: Extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.

In immunotherapy, if a dose is missed:

• Less than 1 week late: The usual dose may often be given.
• 1–2 weeks late: The dose may need to be reduced to the previous level.
• More than 3 weeks late: The build-up process may need to be restarted at a much lower concentration.

An overdose of Cetraria Islandica Subsp. Islandica allergenic extract typically manifests as an exaggerated allergic response.

• Signs: Massive local swelling at the injection site, hives (urticaria), angioedema (swelling of the face/throat), wheezing, or a drop in blood pressure (anaphylactic shock).
• Emergency Measures: Immediate administration of intramuscular epinephrine, followed by antihistamines and corticosteroids. Seek emergency medical care immediately if an overdose is suspected.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip maintenance injections without medical guidance, as this increases the risk of adverse reactions.

Side effects are most frequently localized to the site of administration.

• Local Redness (Erythema): A red patch at the injection or prick site is expected and typically resolves within a few hours.
• Itching (Pruritus): Intense itching at the site of contact is common as histamine is released.
• Swelling (Wheal): A raised, white or red bump (similar to a mosquito bite) is the standard diagnostic response but may be uncomfortable.
• Throat Numbness: When used in lozenge form, a mild, temporary coating or numbing sensation in the mouth is common.

• Large Local Reactions: Swelling that exceeds 10cm in diameter at the injection site, which may be painful and last for 24–48 hours.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy injection.
• Headache: Mild to moderate tension-type headaches have been reported following systemic exposure to lichen extracts.
• Gastrointestinal Upset: If ingested in high quantities, the bitter lichen acids may cause mild nausea or abdominal cramping.

• Generalized Urticaria: Hives appearing on parts of the body far from the injection site.
• Rhinitis: Sneezing, runny nose, or nasal congestion occurring shortly after administration.
• Dizziness: A feeling of lightheadedness, which may be a precursor to a more serious systemic reaction.

> Warning: Stop taking Cetraria Islandica Subsp. Islandica and call your doctor immediately if you experience any of these symptoms of anaphylaxis:

• Difficulty Breathing: Wheezing, chest tightness, or shortness of breath (bronchospasm).
• Swelling of the Tongue or Throat: Feeling like the throat is closing or difficulty swallowing (angioedema).
• Rapid or Weak Pulse: Signs of cardiovascular distress or impending shock.
• Severe Hypotension: A sudden drop in blood pressure leading to fainting or loss of consciousness.
• Cyanosis: Bluish tint to the lips, skin, or fingernails indicating lack of oxygen.

With prolonged use in immunotherapy, the goal is to induce immune tolerance. However, long-term risks include:

• Persistent Subcutaneous Nodules: Small, firm lumps may form at the site of repeated injections.
• Immunological Shifts: While generally beneficial, long-term modulation of the immune system requires monitoring to ensure no development of other hypersensitivities, though this is rare.
• Chronic Lichenoid Dermatitis: In very rare cases, chronic exposure to certain lichen components can lead to a persistent skin rash resembling lichen planus.

As of 2026, many allergenic extracts, including non-standardized ones like Cetraria Islandica Subsp. Islandica, carry a class-wide warning regarding the risk of Severe Anaphylaxis.

Summary of Warning: This product can cause severe, life-threatening allergic reactions, including anaphylaxis. It must only be administered by healthcare professionals prepared to manage such reactions. Patients with unstable asthma are at increased risk for fatal outcomes. Healthcare providers must observe patients for at least 30 minutes after administration.

Report any unusual symptoms, even if they seem minor, to your healthcare provider immediately. Early intervention is key to managing systemic reactions.

Cetraria Islandica Subsp. Islandica is a potent biological substance. It is not a standard medication but an immunological tool. Patients must be aware that the primary risk is an overreaction of the immune system. It is essential to provide a full medical history, specifically regarding any history of asthma, heart disease, or previous reactions to lichen-based products (such as certain perfumes or oakmoss extracts).

No FDA black box warnings for Cetraria Islandica Subsp. Islandica specifically, but it is subject to the general FDA warnings for Allergenic Extracts. These warnings emphasize that systemic reactions are a constant risk and that the extract should not be used in patients with severe, unstable, or steroid-dependent asthma, as they are at the highest risk for fatal bronchospasm during a reaction.

• Allergic Reactions / Anaphylaxis Risk: This is the most significant concern. Anaphylaxis can occur even in patients who have previously tolerated the extract. The risk is higher during the build-up phase of immunotherapy.
• Asthma Exacerbation: Patients with active asthma symptoms should delay their injection or testing until their asthma is well-controlled. Bronchospasm triggered by the extract can be severe.
• Cardiovascular Risk: Patients taking beta-blockers may be resistant to the effects of epinephrine, which is the primary treatment for anaphylaxis. This makes any allergic reaction significantly more dangerous.
• Autoimmune Conditions: Use with caution in patients with active autoimmune diseases, as the immunomodulatory effects of the lichen polysaccharides (beta-glucans) could theoretically exacerbate these conditions.

• Observation Period: A mandatory 30-minute wait in the clinic after every injection.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before and after administration to ensure no significant drop in lung function.
• Skin Assessment: Regular checks of the injection site for large local reactions, which may necessitate a dose reduction.

Generally, Cetraria Islandica Subsp. Islandica does not cause drowsiness. However, if a systemic reaction occurs or if the patient receives antihistamines to treat a local reaction, their ability to drive or operate machinery may be impaired. Patients should wait until they are certain they are not experiencing a delayed reaction before driving.

Alcohol should be avoided on the day of an immunotherapy injection. Alcohol can increase peripheral vasodilation (widening of blood vessels), which may accelerate the absorption of the allergen or worsen the symptoms of an allergic reaction.

• Tapering: Tapering is not required for this extract, as it does not cause physical dependence.
• Withdrawal: There is no withdrawal syndrome. However, stopping immunotherapy prematurely will likely result in the return of allergy symptoms upon natural exposure to the lichen.

> Important: Discuss all your medical conditions, especially respiratory and heart issues, with your healthcare provider before starting Cetraria Islandica Subsp. Islandica.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are strictly contraindicated or used with extreme caution during immunotherapy. They block the beta-adrenergic receptors, making epinephrine (Adrenalin) ineffective if it is needed to treat a life-threatening allergic reaction.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of sympathomimetics used to treat reactions, leading to hypertensive crises.

• ACE Inhibitors (e.g., Lisinopril): Some evidence suggests that ACE inhibitors may increase the risk of more severe systemic reactions to allergenic extracts or interfere with the body's compensatory mechanisms during anaphylaxis.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can interfere with the management of an allergic reaction by altering the response to emergency medications.

• Antihistamines (e.g., Cetirizine, Loratadine): These must be discontinued several days (usually 3–7 days) before diagnostic skin testing. Antihistamines block the H1 receptors, which prevents the 'wheal and flare' response, leading to a false-negative test result. They do not, however, need to be stopped for maintenance immunotherapy unless directed by a doctor.
• Corticosteroids (Systemic): High doses of oral steroids (like Prednisone) can suppress the immune response and may mask or diminish the results of diagnostic tests.

• High-Fat Meals: No direct interaction with the extract, but heavy meals may complicate the management of nausea if a systemic reaction occurs.
• Alcohol: As mentioned, alcohol can increase the rate of allergen absorption and should be avoided.

• St. John's Wort: May theoretically affect the metabolism of lichen acids through CYP3A4 induction, though the clinical significance is low for allergenic extracts.
• Immune Stimulants (e.g., Echinacea): These may interfere with the desensitization goals of immunotherapy by over-activating the immune system.

• Skin Prick Tests: The extract itself is the subject of the test. However, other skin tests (like those for tuberculosis) should ideally not be performed on the same day to avoid diagnostic confusion.
• Ammonia Levels: Because of its Ammonium Ion Binding Activity [MoA], very high systemic doses (unlikely in standard allergy use) could theoretically interfere with blood ammonia laboratory results.

Mechanism of Interactions: Most interactions are pharmacodynamic (affecting the body's response to the drug) rather than pharmacokinetic. The primary concern is the interference with the diagnosis of an allergy or the treatment of a reaction.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any 'heart' or 'blood pressure' pills.

Cetraria Islandica Subsp. Islandica must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume (FEV1) consistently below 70% of predicted values are at high risk for fatal reactions.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3–6 months. The stress of a potential systemic reaction could trigger another cardiac event.
3. 3Previous Severe Anaphylaxis to Lichen: If a patient has had a life-threatening reaction to Cetraria Islandica specifically in the past, further use is contraindicated unless in a highly specialized desensitization protocol.
4. 4Active Malignancy: Immunotherapy may theoretically interfere with certain cancer treatments or the immune system's focus on the tumor.

Conditions requiring a careful risk-benefit analysis include:

• Pregnancy: While not strictly contraindicated for maintenance, starting a new course of immunotherapy during pregnancy is generally avoided due to the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen).
• Autoimmune Disorders: Such as Lupus or Rheumatoid Arthritis, where immune stimulation could cause a flare.
• Beta-Blocker Therapy: As discussed, this makes managing reactions difficult.

Patients allergic to Cetraria Islandica Subsp. Islandica may also react to:

• Usnea Species (Old Man's Beard): Contains similar lichen acids (e.g., usnic acid).
• Evernia Prunastri (Oakmoss): Commonly used in perfumes; cross-reactivity is high due to shared depsides and depsidones.
• Certain Fungi: Because lichens are partly fungal, some cross-reactivity with other non-standardized fungal extracts may occur.

> Important: Your healthcare provider will evaluate your complete medical history and current medications before prescribing or administering this extract.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Cetraria Islandica Subsp. Islandica in pregnant women. Animal reproduction studies have not been conducted.

• Risk Summary: The primary risk to the fetus is maternal anaphylaxis, which can lead to uterine contractions, placental abruption, or fetal death due to oxygen deprivation.
• Clinical Considerations: It is generally recommended that immunotherapy be maintained at the current dose if the patient is already in the maintenance phase and tolerating it well. However, dose escalation (the build-up phase) should be suspended until after delivery.

It is not known whether the components of Cetraria Islandica Subsp. Islandica are excreted in human milk. Because many proteins and lichen acids have high molecular weights or undergo rapid degradation, significant exposure to the nursing infant is unlikely. However, the risk of maternal anaphylaxis remains a concern for the mother's ability to care for the infant. A risk-benefit discussion with a healthcare provider is essential.

• Approved Age: Generally used in children 5 years and older for immunotherapy. Diagnostic testing can be performed in younger children if the clinical need is high.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development in children.
• Special Considerations: Children must be able to sit still for the observation period and communicate symptoms of 'itchy throat' or 'funny feeling' which may signal an impending reaction.

• Pharmacokinetic Changes: Reduced skin turgor and capillary density in the elderly may lead to smaller wheal responses during testing, potentially requiring intradermal follow-up if prick tests are negative.
• Safety: The elderly are more likely to have underlying cardiovascular disease, making them more vulnerable to the effects of a systemic reaction or the epinephrine used to treat it.
• Polypharmacy: Increased likelihood of being on beta-blockers or ACE inhibitors, which complicates the safety profile.

In patients with chronic kidney disease (CKD), the clearance of lichen acids may be reduced. While this is rarely an issue for diagnostic testing, for those receiving high-dose immunotherapy, providers should monitor for signs of systemic toxicity, although specific GFR-based dosing tables do not exist for this biological extract.

For patients with liver cirrhosis or hepatitis, the processing of secondary lichen metabolites (like cetraric acid) may be impaired. These patients should be monitored for any unusual systemic symptoms, particularly if they are consuming oral lichen preparations alongside receiving injections.

> Important: Special populations require individualized medical assessment and often more conservative dosing strategies.

Cetraria Islandica Subsp. Islandica acts as a complex antigen. Its primary molecular mechanism in an allergic context is the cross-linking of IgE antibodies on the surface of mast cells. This triggers the degranulation process, releasing histamine, leukotrienes, and prostaglandins.

In its role as a Nitrogen Binding Agent [EPC], the lichen contains specific organic acids (depsidones) that possess Ammonium Ion Binding Activity [MoA]. These compounds can form stable complexes with ammonium ions, potentially reducing the concentration of free ammonia in a localized environment. Furthermore, the polysaccharide Lichenin acts as an immunomodulator by binding to Dectin-1 receptors on myeloid cells, which can shift the T-helper cell response from a Th2 (pro-allergic) profile to a Th1 profile over long-term immunotherapy.

• Dose-Response: In skin testing, the size of the wheal is generally proportional to the degree of sensitization, up to a plateau. In immunotherapy, the dose-response is aimed at increasing the threshold of allergen exposure required to trigger symptoms.
• Onset of Effect: Diagnostic skin reactions appear within 15–20 minutes. The therapeutic effect of immunotherapy (desensitization) typically takes 3–6 months to become noticeable and 1–3 years to reach peak efficacy.
• Duration: Diagnostic wheals resolve in 2–4 hours. Therapeutic effects can persist for several years after a 3-to-5-year course of treatment is completed.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous), Variable (Oral) |

| Protein Binding | High (Lichen acids), Variable (Antigens) |

| Half-life | 2–6 hours (Lichen acids) |

| Tmax | 15–30 minutes (Local), 1–2 hours (Systemic) |

| Metabolism | Hepatic (Lichen acids); Proteolysis (Antigens) |

| Excretion | Renal (Metabolites); Fecal (Unabsorbed Polysaccharides) |

• Molecular Formula: Complex mixture (Lichenin: (C6H10O5)n; Usnic acid: C18H16O7).
• Molecular Weight: Varies (Lichenin ~20,000–200,000 Da).
• Solubility: Polysaccharides are soluble in hot water; lichen acids are poorly soluble in water but soluble in organic solvents or alkaline solutions.
• Structure: A symbiotic thallus containing fungal hyphae (Ascomycota) and green algae (Trebouxia).

Cetraria Islandica Subsp. Islandica is classified as a Non-Standardized Food Allergenic Extract [EPC]. Related medications include other lichen-derived extracts (like Usnea) and broader plant extracts used in the 'Northern Allergen Panel'. It is also grouped under Nitrogen Binding Agents in specific biochemical contexts.